A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Our growing product portfolio is purposefully designed to leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. We are committed to delivering our advanced technologies with a strong economic value proposition to assist surgeons and institutions in providing next-generation soft-tissue repair solutions to more patients worldwide. We are dedicated to building true partnerships with surgeons and healthcare providers to deliver solutions that provide both clinical and economic improvements.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 77M | 69M | 58M | 41M | 29M | 18M |
| Net Income | -39M | -38M | -47M | -44M | -33M | -29M |
| EPS | $-0.83 | $-1.33 | $-2.04 | $-2.72 | $-2.30 | $-2.23 |
| Free Cash Flow | -32M | -43M | -41M | -42M | -31M | -25M |
| ROIC | -210.0% | -54.4% | -78.6% | -81.7% | -115.8% | -36.1% |
| Gross Margin | 67.2% | 67.1% | 68.6% | 65.3% | 63.9% | 61.7% |
| Debt/Equity | 26.65 | 1.45 | 2.15 | 2.79 | 2.11 | 0.63 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -35M | -34M | -44M | -39M | -29M | -25M |
| Operating Margin | -46.0% | -49.2% | -75.4% | -94.2% | -100.0% | -138.8% |
| ROE | -2504.7% | -159.9% | -247.1% | -309.7% | -165.6% | -58.7% |
| Shares Outstanding | 40M | 28M | 23M | 16M | 14M | 13M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | N/A | 15M | 18M | 29M | 41M | 58M | 69M | 77M |
| Gross Margin | N/A | 60.0% | 61.7% | 63.9% | 65.3% | 68.6% | 67.1% | 67.2% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -18M | -19M | -25M | -29M | -39M | -44M | -34M | -35M |
| Op. Margin | N/A | -124.1% | -138.8% | -100.0% | -94.2% | -75.4% | -49.2% | -46.0% |
| Net Income | -30M | -30M | -29M | -33M | -44M | -47M | -38M | -39M |
| Net Margin | N/A | -195.6% | -158.1% | -112.9% | -106.9% | -79.8% | -54.6% | -50.6% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -51.6% | -49.4% | -36.1% | -115.8% | -81.7% | -78.6% | -54.4% | N/M |
| ROE | N/A | -97.6% | -58.7% | -165.6% | -309.7% | -247.1% | -159.9% | -2504.7% |
| ROA | -109.9% | -44.5% | -33.3% | -53.2% | -65.3% | -59.8% | -46.0% | -63.3% |
| Cash Flow | ||||||||
| Op. Cash Flow | -20M | -26M | -24M | -30M | -41M | -41M | -42M | -31M |
| Free Cash Flow | -20M | -26M | -25M | -31M | -42M | -41M | -43M | -32M |
| Owner Earnings | -21M | -26M | -27M | -34M | -45M | -46M | -47M | -36M |
| CapEx | 62K | 197K | 167K | 627K | 872K | 611K | 989K | 621K |
| Maint. CapEx | 463K | 278K | 221K | 231K | 383K | 428K | 632K | 632K |
| Growth CapEx | 0 | 0 | 0 | 396K | 489K | 183K | 357K | 0 |
| D&A | 463K | 278K | 221K | 231K | 383K | 428K | 632K | 632K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 216K | 457K | 2.1M | 3.7M | 4.0M | 5.0M | 4.4M | 4.4M |
| Debt Repayment | 13M | 0 | 0 | 0 | 30M | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | N/A | -24M | -44M | N/A | -2.1M | -6.2M | -12M | 12M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 30M |
| Long-Term Debt | N/A | 30M | 31M | N/A | 40M | 41M | 41M | 41M |
| Debt/Equity | -1.20 | 0.98 | 0.63 | 2.11 | 2.79 | 2.15 | 1.45 | 26.65 |
| Interest Coverage | -9.9 | -5.3 | -7.1 | -8.2 | -9.6 | -8.4 | -6.4 | -6.4 |
| Equity | -138M | 31M | 49M | 20M | 14M | 19M | 28M | 1.6M |
| Total Assets | 27M | 68M | 86M | 63M | 68M | 78M | 87M | 62M |
| Total Liabilities | 165M | 37M | 37M | 42M | 54M | 59M | 58M | 60M |
| Intangibles | 6.4M | 5.8M | 5.2M | 4.6M | 5.0M | 4.2M | 3.5M | 3.5M |
| Retained Earnings | -138M | -168M | -197M | -230M | -274M | -321M | -359M | -359M |
| Working Capital | 14M | 58M | 77M | 48M | 50M | 55M | 62M | 62M |
| Current Assets | 23M | 64M | 83M | 59M | 62M | 72M | 78M | 78M |
| Current Liabilities | 9.6M | 6.7M | 6.6M | 11M | 12M | 17M | 16M | 16M |
| Per Share Data | ||||||||
| EPS | -2.62 | -17.10 | -2.23 | -2.30 | -2.72 | -2.04 | -1.33 | -0.83 |
| Owner EPS | -1.81 | -1.82 | -2.07 | -2.37 | -2.77 | -2.02 | -1.64 | -0.89 |
| Book Value | -12.09 | 2.14 | 3.80 | 1.39 | 0.88 | 0.83 | 1.00 | 0.04 |
| Cash Flow/Share | -1.75 | -1.77 | -1.89 | -2.10 | -2.50 | -1.79 | -1.46 | -0.95 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 11.4M | 14.4M | 12.9M | 14.5M | 16.3M | 22.9M | 28.5M | 40.3M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.7 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 5.9 | 4.2 | 9.0 | 13.0 | 7.6 | 2.9 | 15.6 |
| Price/Sales | N/A | 11.4 | 10.1 | 6.8 | 3.7 | 3.6 | 1.9 | 0.3 |
| FCF Yield | N/A | -14.1% | -12.1% | -17.2% | -22.4% | -28.7% | -51.4% | -129.7% |
| Market Cap | N/A | 183M | 203M | 180M | 186M | 144M | 83M | 24M |
| Avg. Price | N/A | 12.20 | 14.22 | 13.87 | 9.44 | 9.11 | 4.55 | 0.60 |
| Year-End Price | N/A | 12.65 | 15.76 | 12.45 | 11.40 | 6.31 | 2.91 | 0.60 |
TELA Bio, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 65.3%.
TELA Bio, Inc. (TELA) has a 5-year average return on invested capital (ROIC) of -73.3%. This is below average and may indicate limited pricing power.
TELA Bio, Inc. (TELA) has a market capitalization of $24M. It is classified as a small-cap stock.
TELA Bio, Inc. (TELA) does not currently pay a regular dividend.
TELA Bio, Inc. (TELA) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
TELA Bio, Inc. (TELA) reported annual revenue of $69 million in its most recent fiscal year, based on SEC EDGAR filings.
TELA Bio, Inc. (TELA) has a net profit margin of -54.6%. The company is currently unprofitable.
TELA Bio, Inc. (TELA) generated $-43 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
TELA Bio, Inc. (TELA) has a debt-to-equity ratio of 1.45. This indicates moderate leverage.
TELA Bio, Inc. (TELA) reported earnings per share (EPS) of $-1.33 in its most recent fiscal year.
TELA Bio, Inc. (TELA) has a return on equity (ROE) of -159.9%. A negative ROE may indicate losses or negative equity.
TELA Bio, Inc. (TELA) has a 5-year average gross margin of 65.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 7 years of financial data for TELA Bio, Inc. (TELA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
TELA Bio, Inc. (TELA) has a book value per share of $1.00, based on its most recent annual SEC filing.